Dr. Michael Chu Conducts World-Class ...

Dr. Michael Chu, MD

Claim this profile

London Health Sciences Centre

Studies Coronary Artery Disease
Studies Stroke
17 reported clinical trials
26 drugs studied

Affiliated Hospitals

Image of trial facility.
London Health Sciences Centre
Image of trial facility.
London Health Sciences Centre - University Campus

Clinical Trials Michael Chu, MD is currently running

Image of trial facility.

Hemiarch vs Extended Arch Surgery

for Aortic Dissection

HEADSTART is a prospective, open-label, non-blinded, multicenter, randomized controlled trial that compares a composite of mortality and re-intervention in patients undergoing hemiarch and extended arch repair for acute DeBakey type 1 aortic dissection. Eligible patients will be randomized to one or the other surgical strategy and clinical and imaging outcome data will be collected over a 3 year follow up period.
Recruiting1 award N/A3 criteria
Image of trial facility.

Heart Surgery

for Coronary Artery Disease

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with multivessel/left main (LM) coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF). The primary objective is to determine whether CABG compared to PCI is associated with a reduction in all-cause death, stroke, spontaneous myocardial infarction (MI), urgent repeat revascularization (RR), or heart failure (HF) readmission over a median follow-up of 5 years in patients with multivessel/LM CAD and ischemic left ventricular dysfunction (iLVSD). Eligible patients are considered by the local Heart Team appropriate and amenable for non-emergent revascularization by both modes of revascularization. The secondary objectives are to describe the early risks of both procedures, and a comprehensive set of patient-reported outcomes longitudinally.
Recruiting1 award N/A4 criteria

More about Michael Chu, MD

Clinical Trial Related4 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 8 Active Clinical Trials
Treatments Michael Chu, MD has experience with
  • Autologous CD19-directed Chimeric Antigen Receptor (CAR) T-cells
  • Revascularization By PCI
  • Revascularization By CABG
  • Oral Anticoagulant
  • Antiplatelet-only Strategy
  • Multiple Arterial Grafting

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Michael Chu, MD specialize in?
Is Michael Chu, MD currently recruiting for clinical trials?
Are there any treatments that Michael Chu, MD has studied deeply?
What is the best way to schedule an appointment with Michael Chu, MD?
What is the office address of Michael Chu, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security